Skip to main content

Refractory Malignant Solid Neoplasm clinical trials at UCSF

23 in progress, 8 open to eligible people

Refractory malignant solid neoplasm means cancer that doesn't respond to treatment. UCSF has many clinical trials for this kind of cancer. Trials include testing a new drug called tegavivint, seeing how well tiragolumab and atezolizumab work, and studying ivosidenib, selpercatinib, larotrectinib, samotolisib, and ensartinib. The Pediatric MATCH Screening Trial may help match patients with the best treatment based on their genetics.

Showing trials for

Our lead scientists for Refractory Malignant Solid Neoplasm research studies include .

Last updated: